CD4 and cancer: Taken together, adiponectin-expressing tTreg precursors elicit anti-cancer activity at least partly by facilitating T-cell selection in TNC complexes, suppressing the release of immature CD4+CD8+ cells from thymus, and promoting the immune cell recruitment within the tumor microenvironment.